Immunology Drugs Market Report Suite for the United States, 2018-2024, iData Pharma MedSuite

Immunology Drugs Market Report Suite for the United States, 2018-2024, iData Pharma MedSuite

  • April 2018 •
  • 1052 pages •
  • Report ID: 5748072 •
  • Format: PDF
The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost-effective drugs in treating these diseases, there is also an increased number of drugs in development for the same. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. This report covers second-line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

Abstract
The United States immunology drugs report provides market analysis, sizing, forecasts, dosage units sold, average selling prices, and market shares of the immunology drugs within 5 major diseases. The report analyses key factors instrumental in changing the market scenario and provides a forecast of the future immunology market in the United States. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.

Scope
2013-2023